Comunicaciones Celulares S.A. Resolves DOJ Investigation Related to Historical Conduct Comunicaciones Celulares S.A. Resolves DOJ Investigation Related to Historical Conduct Luxembourg, November 10, 2025 – Millicom International Cellular S.A. (“Millicom”) today announced that its subsidiary, Comunicaciones Celulares S.A. (“Comcel”), has reached an agreement with the U.S. Department of Justice (“DOJ”) to resolve an investigation concerning historical improper payments made to Guatemalan government officials. At the time of the conduct, Comcel operated as a joint venture over which Millico...
Millicom (Tigo) Q3 2025 Earnings Release Millicom (Tigo) Q3 2025 Earnings Release Luxembourg, November 6, 2025 – is pleased to announce its third quarter 2025 results. Please find below links to the Q3 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q3 2025 Highlights* Revenue $1.42 billion Operating profit $390 million, and record Adjusted EBITDA $695 million Net profit attributable to company owners $195 million, including approximately $138 million net profit from the closure of infrastructure transactions Equity free cash flow $243 million ...
Three Directors at Swedish Orphan Biovitrum AB sold after exercising options/sold 208,150 shares at between 324.800SEK and 324.856SEK. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
Millicom (Tigo) notice of third quarter 2025 results and video conference Millicom (Tigo) notice of third quarter 2025 results and video conference Luxembourg, October 16, 2025 – Millicom (NASDAQ: TIGO) expects to announce its third quarter 2025 results on November 6, 2025, via a press release. Millicom is planning to host a video conference for the global financial community on November 6, 2025, at 08:00 (New York) / 13:00 (London). Registration for the interactive event is required at the following . After registering, you will receive a confirmation email containing details about j...
Millicom (Tigo) completes acquisition of Telefónica in Uruguay, strengthening its regional footprint in South America Millicom (Tigo) completes acquisition of Telefónica in Uruguay, strengthening its regional footprint in South America Luxembourg, October 7, 2025 – Millicom International Cellular S.A. (“Millicom”) today announced that, following final approval from the Government of Uruguay, it has completed the acquisition of 100% of Telefónica Móviles del Uruguay S.A. (Movistar) for an enterprise value of USD 440 million. With this milestone transaction, Millicom officially enters the Ur...
Millicom (Tigo) subsidiary Telefónica Celular del Paraguay S.A.E. announces its intent to partially redeem Senior Notes due 2027 Luxembourg, September 5, 2025 – Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E (“Telecel Paraguay”) today announced its intent to redeem $150,000,000 aggregate principal amount of its 5.875% Senior Unsecured Notes due 2027 (the “Notes”) on September 15, 2024 (the “Redemption Date”). A notice of redemption will be sent to the holders of the Notes in accordance with the requirements of the indenture governing the Notes (the “Indenture”). Pursuant to the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.